Updates on Recent Advancements in Hepatitis D Virus Treatment

Bardak A. E., Ozturk N. B., Gurakar M., Sequeira L., Yildiz E., Ozmert E. H., ...Daha Fazla

Viruses, cilt.17, sa.8, 2025 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 17 Sayı: 8
  • Basım Tarihi: 2025
  • Doi Numarası: 10.3390/v17081100
  • Dergi Adı: Viruses
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, Food Science & Technology Abstracts, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
  • Anahtar Kelimeler: antisense oligonucleotide, bulevirtide, HDV, hepatitis D virus, interferon lambda, lonafarnib, nucleic acid polymer, small interfering RNA
  • Ankara Üniversitesi Adresli: Evet

Özet

Hepatitis D virus (HDV) infection remains a major cause of severe liver disease among hepatitis B virus (HBV)-infected patients, contributing to accelerated progression to cirrhosis and hepatocellular carcinoma. Pegylated interferon-α remains the first-line therapy for chronic HDV infection in most cases. However, despite its approval for HBV and hepatitis C virus (HCV) infections, its use in HDV is largely driven by a lack of other options and is constrained by its limited efficacy, suboptimal durability of response, and a substantial side effect profile. Meanwhile, bulevirtide, an entry inhibitor, became the first agent to be approved for use in chronic HDV infections by the European Medicines Agency (EMA), and several other therapies are currently being investigated as well. In this review, we provide updates on recent advancements in HDV treatment and novel therapies.